Correlation Between Changes in Sex Hormone Levels and Stress Urinary Incontinence in Women

Launched by RENJI HOSPITAL · Oct 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between stress urinary incontinence (a condition that causes involuntary leakage of urine during activities that put pressure on the bladder, like exercise or sneezing) and certain hormones in women. Researchers want to understand how changes in hormones, specifically androgens and estrogens, might affect the occurrence and severity of this condition. They will compare women who have stress urinary incontinence with those who do not, looking for any significant differences in hormone levels.

To participate, women must be at least 20 years old. Those in the experimental group will have been diagnosed with stress urinary incontinence at the hospital and will undergo hormone tests. Women in the control group will have other medical conditions but will also be at least 20 years old and have undergone the same hormone tests. Participants will provide basic health information and have their hormone levels measured. This study is not yet recruiting, so it's a great opportunity to learn more about how hormones might relate to urinary incontinence. If you're considering joining, it's important to know that some conditions like pelvic organ prolapse or recent hormone therapy would exclude you from participation.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Experimental Group
• • 1. women aged ≥20 years
• • 2. Stress urinary incontinence diagnosed in our hospital;
• • 3. Six hormone tests were performed in our hospital; Control group
• • (1) women aged ≥20 years; (2) diseases other than stress urinary incontinence diagnosed by our hospital; (2) Six hormone tests were performed in our hospital;
• Exclusion Criteria:
• • 1. Pelvic organ prolapse, overactive bladder, urge urinary incontinence, overflow urinary incontinence, mixed urinary incontinence;
• • 2. patients who received hormone replacement therapy within 6 months;
• • 3. estrogen-dependent diseases, such as endometriosis, uterine leiomyoma, ovarian tumors;
• • 4. the presence of gynecological malignant tumors or other diseases affecting hormone secretion;
• • 5. the presence of nervous system diseases.